【摘要】：21世紀是生物的時代，各國都加大了生物領(lǐng)域的投入，生物制藥產(chǎn)業(yè)是重中之重。我國也加大了對生物制藥產(chǎn)業(yè)的投入，從“十五”期間的10億的研發(fā)投入，到“十二五”期間的100億投入，我國生物制藥產(chǎn)業(yè)發(fā)展已被提升到了一個全新的高度。但與國外生物制藥企業(yè)相比，我國生物制藥企業(yè)由于研發(fā)投入不足，企業(yè)規(guī)模小等因素，造成企業(yè)技術(shù)效率低下。本文通過對我國生物制藥企業(yè)的技術(shù)效率進行測算并對效率低下的原因進行分析，希望找出影響生物制藥企業(yè)技術(shù)效率低下的原因及提高生物制藥企業(yè)效率的方法和途徑。 本文以技術(shù)經(jīng)濟與項目管理等相關(guān)理論為基礎(chǔ)，對國內(nèi)外的生物制藥企業(yè)研究現(xiàn)狀和DEA、SFA方法應(yīng)用情況進行了論述，并對DEA和SFA方法原理進行了詳細的介紹。結(jié)合我國141家上市生物制藥企業(yè)的實際，對我國生物制藥企業(yè)的概況進行分析。以勞動、資本和知識存量為投入指標，主營業(yè)務(wù)收入為產(chǎn)出指標，用DEA和SFA的方法對我國20家上市生物制藥企業(yè)的技術(shù)效率進行測算。對兩種方法測算結(jié)果進行比較，得出DEA和SFA兩種方法所得結(jié)果具有一致性。在此基礎(chǔ)上，用SFA方法對影響企業(yè)技術(shù)效率的因素進行了分析，找出了影響企業(yè)效率的正面因素和負面因素。最后對改善生物制藥企業(yè)技術(shù)效率提出了幾點建議。 分析得出，生物制藥企業(yè)是高新技術(shù)企業(yè)，盲目地增加企業(yè)員工數(shù)量不能提高企業(yè)的主營業(yè)務(wù)收入；提高企業(yè)知識存量，擴大企業(yè)規(guī)模，，有利于提高生物制藥企業(yè)主營業(yè)務(wù)收入。對影響因素進行分析指出：新藥和專利數(shù)、國有股比例、科研機構(gòu)合作水平、融資能力、研發(fā)費用占主營業(yè)務(wù)比例和產(chǎn)業(yè)聚集度對提高企業(yè)技術(shù)效率有正的影響；研發(fā)人員比例、股權(quán)激勵、企業(yè)家精神和能力對生物制藥企業(yè)技術(shù)效率有不顯著的負向影響。 本研究不僅對生物制藥企業(yè)的技術(shù)效率進行了測算和分析，還進一步證明了DEA和SFA方法在評價生物制藥企業(yè)技術(shù)效率的合理性。同時還創(chuàng)新性的對影響技術(shù)效率定性因素進行了量化，為其他類型企業(yè)的技術(shù)效率評估提供了參考。
[Abstract]:The 21st century is the era of biology, all countries have increased the investment in biological field, biopharmaceutical industry is the most important. China has also increased its investment in the biopharmaceutical industry. From the 1 billion R & D investment during the 10th Five-Year Plan period to the 10 billion investment in the 12th Five-Year Plan period, the development of the biopharmaceutical industry in China has been promoted to a new height. However, compared with foreign biopharmaceutical enterprises, Chinese biopharmaceutical enterprises have low technical efficiency due to insufficient R & D investment and small scale of enterprises. By measuring the technical efficiency of the biopharmaceutical enterprises in China and analyzing the causes of the inefficiency, this paper hopes to find out the reasons that affect the technical inefficiency of the biopharmaceutical enterprises and the methods and ways to improve the efficiency of the biopharmaceutical enterprises. Based on the theories of technology economy and project management, this paper discusses the present research situation and the application of DEA,SFA method in biopharmaceutical enterprises at home and abroad, and introduces the principles of DEA and SFA methods in detail. Based on the practice of 141 listed biopharmaceutical enterprises in China, the general situation of Chinese biopharmaceutical enterprises is analyzed. Taking labor, capital and knowledge stock as input index and main business income as output index, the technical efficiency of 20 listed biopharmaceutical enterprises in China was measured by DEA and SFA. By comparing the results of the two methods, the results of DEA and SFA are consistent. On this basis, this paper analyzes the factors that affect the efficiency of enterprise technology by SFA method, and finds out the positive and negative factors that affect the efficiency of enterprises. Finally, some suggestions are put forward to improve the technical efficiency of biopharmaceutical enterprises. The analysis shows that biopharmaceutical enterprises are high and new technology enterprises, so blindly increasing the number of employees can not improve the main business income of enterprises, improve the knowledge stock of enterprises, and expand the scale of enterprises. It helps to improve the income of the main business of biopharmaceutical enterprises. It is pointed out that the number of new drugs and patents, the proportion of state-owned shares, the level of cooperation of scientific research institutions, the ability of financing, the proportion of R & D expenses to the main business and the degree of industrial agglomeration have positive effects on improving the technical efficiency of enterprises; The proportion of R & D personnel, equity incentive, entrepreneurship and ability have no significant negative impact on the technical efficiency of biopharmaceutical enterprises. This study not only measures and analyzes the technical efficiency of biopharmaceutical enterprises, but also proves the rationality of DEA and SFA methods in evaluating the technical efficiency of biopharmaceutical enterprises. At the same time, the qualitative factors that affect the technical efficiency are quantified creatively, which provides a reference for the evaluation of the technological efficiency of other types of enterprises.
【學(xué)位授予單位】：西北農(nóng)林科技大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2013
【分類號】：F273.1;F426.72

【參考文獻】

相關(guān)期刊論文 前10條

1 韓晶;;基于SFA方法的中國制造業(yè)創(chuàng)新效率研究[J];北京師范大學(xué)學(xué)報(社會科學(xué)版);2010年06期

2 李然;馮中朝;;環(huán)境效應(yīng)和隨機誤差的農(nóng)戶家庭經(jīng)營技術(shù)效率分析——基于三階段DEA模型和我國農(nóng)戶的微觀數(shù)據(jù)[J];財經(jīng)研究;2009年09期

3 孫建;DEA在企業(yè)效率評價中的應(yīng)用研究[J];地質(zhì)技術(shù)經(jīng)濟管理;2003年05期

4 張醒洲,王春艷;生物制藥企業(yè)成功要素[J];大連理工大學(xué)學(xué)報(社會科學(xué)版);2002年04期

5 張慶芝;何楓;趙曉;;基于SFA的能源消耗、代理成本及股權(quán)結(jié)構(gòu)與鋼鐵企業(yè)效率關(guān)系研究[J];管理學(xué)報;2011年07期

6 張蕊,田澎;生物制藥產(chǎn)業(yè)現(xiàn)狀分析及我國企業(yè)的發(fā)展戰(zhàn)略[J];工業(yè)工程與管理;2005年05期

7 伍青;;基于超效率DEA模型的上市軍工企業(yè)經(jīng)營效率分析[J];湖南師范大學(xué)社會科學(xué)學(xué)報;2007年04期

8 黃麗娜;蔡虹;;企業(yè)R&D投資經(jīng)濟效果的實證分析[J];科技管理研究;2007年08期

9 鮑學(xué)東;鄭循剛;;基于SFA的四川農(nóng)業(yè)生產(chǎn)技術(shù)效率分析[J];科技管理研究;2008年09期

10 張冬平,馮繼紅;我國小麥生產(chǎn)效率的DEA分析[J];農(nóng)業(yè)技術(shù)經(jīng)濟;2005年03期

相關(guān)博士學(xué)位論文 前1條

1 周德勝;生物制藥產(chǎn)業(yè)化影響因素及作用機理研究[D];大連理工大學(xué);2008年

相關(guān)碩士學(xué)位論文 前5條

1 李嘉雋;基于SFA和DEA法的中國上市銀行收入技術(shù)效率研究[D];南京航空航天大學(xué);2011年

2 王啟鳳;我國生物制藥上市公司的經(jīng)營業(yè)績評價[D];廈門大學(xué);2002年

3 房卓;基于DEA和SFA的物流企業(yè)綜合績效評價研究[D];大連理工大學(xué);2006年

4 曲波;長春金海生物制藥有限公司發(fā)展戰(zhàn)略研究[D];吉林大學(xué);2007年

5 公磊;從廈門的某些生物制藥企業(yè)看我國生物制藥行業(yè)的現(xiàn)狀及發(fā)展策略[D];廈門大學(xué);2008年

本文編號：2255413